Page 11 - Activating Construct News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Activating construct. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Activating Construct Today - Breaking & Trending Today

Harpoon Therapeutics Presents Data for New ProTriTAC™ Development Candidates in TROP2- and ITGB6-expressing Solid Tumors at AACR 2023

Results support further investigation of two new ProTriTAC™ protease-activated T cell engager development candidates, with demonstrated therapeutic potential in a broad range of TROP2- and. | April 17, 2023 ....

United States , S Jack Lin , Roberth Uhl , Luke Walker , Exchange Commission , American Association For Cancer Research , Harpoon Therapeutics Inc , Preclinical Development , American Association , Cancer Research , Annual Meeting , Chief Medical Officer , Senior Director , Activating Construct , Harpoon Therapeutics , Private Securities Litigation Reform Act , Harpoon Therapeutic , Nc Stock Exchange , Press Release , F Harp Us41358p1066 ,

Harpoon Therapeutics Presents Data for New ProTriTAC™

Results support further investigation of two new ProTriTAC™ protease-activated T cell engager development candidates, with demonstrated therapeutic. ....

United States , Roberth Uhl , S Jack Lin , Luke Walker , Harpoon Therapeutics Inc , American Association For Cancer Research , Preclinical Development , Exchange Commission , American Association , Cancer Research , Annual Meeting , Chief Medical Officer , Senior Director , Activating Construct , Harpoon Therapeutics , Private Securities Litigation Reform Act , Harpoon Therapeutic , Nasdaq Harp , Harpoon Therapeutics , T Cell ,

Harpoon Therapeutics (NASDAQ:HARP) PT Lowered to $8.00 at Canaccord Genuity Group

Harpoon Therapeutics (NASDAQ:HARP – Get Rating) had its price objective reduced by Canaccord Genuity Group from $16.00 to $8.00 in a research report sent to investors on Monday morning, Benzinga reports. They currently have a buy rating on the stock. Other analysts also recently issued research reports about the stock. HC Wainwright decreased their price […] ....

Ronald Hunt , Blackrock Inc , Piper Sandler , Harpoon Therapeutics Inc , Canaccord Genuity Group , Millennium Management , Renaissance Technologies , Harpoon Therapeutics , Get Rating , Moderate Buy , Therapeutics Stock Down , Director Ronald Hunt , Activating Construct , Harpoon Therapeutics Daily , Nasdaq Harp , Lower Price Target , Canaccord Genuity Group Inc ,

Research Analysts Set Expectations for Harpoon Therapeutics, Inc.'s FY2023 Earnings (NASDAQ:HARP)

Harpoon Therapeutics, Inc. (NASDAQ:HARP – Get Rating) – Stock analysts at Cantor Fitzgerald upped their FY2023 earnings per share estimates for Harpoon Therapeutics in a report released on Wednesday, March 29th. Cantor Fitzgerald analyst J. Kim now forecasts that the company will post earnings of ($1.11) per share for the year, up from their prior […] ....

Ronald Hunt , Canaccord Genuity Group , Piper Sandler , Blackrock Inc , Cantor Fitzgerald , Renaissance Technologies , Vanguard Group Inc , Harpoon Therapeutics Inc , Millennium Management , Harpoon Therapeutics , Get Rating , Harpoon Therapeutic , Genuity Group , Truist Financial , Director Ronald Hunt , Activating Construct , Harpoon Therapeutics Daily , Nasdaq Harp , Earnings Estimates ,

Harpoon Therapeutics (NASDAQ:HARP) PT Lowered to $4.50 at HC Wainwright

Harpoon Therapeutics (NASDAQ:HARP – Get Rating) had its price objective trimmed by HC Wainwright from $7.00 to $4.50 in a report released on Wednesday morning, The Fly reports. The firm currently has a buy rating on the stock. HC Wainwright also issued estimates for Harpoon Therapeutics’ Q1 2023 earnings at ($0.52) EPS, Q2 2023 earnings […] ....

United States , Ronald Hunt , Harpoon Therapeutics Company Profile , Delphia United States Inc , Capital Management , Sequoia Financial Advisors , Harpoon Therapeutics Inc , Harpoon Therapeutics , Get Rating , Truist Financial , Moderate Buy , Director Ronald Hunt , Sigma Investments , Financial Advisors , Activating Construct , Harpoon Therapeutics Daily , Nasdaq Harp , Lower Price Target , Hc Wainwright ,